Harness the rising tide of transformation
Next-generation oncology care demands next-generation precision tests
We’re building upon seven years of medical-AI research to deliver AI tests that ignite biomarker discovery, streamline multimodal diagnostic workflows, and scale precision oncology for patients worldwide.
Why Waiv?
Waiv has evolved to meet this moment
Hundreds of novel innovations are entering clinical development each year, while biomarker testing complexity and costs are surging. As healthcare undergoes a broader shift toward precision care, treatment decisions, monitoring strategies, and patient pathways increasingly rely on high-dimensional data and advanced diagnostics.
Clinical diagnostics must keep pace with the scale and complexity of precision medicine, ensuring no patient is left behind.
Waiv, a spin-out of Owkin, capitalizes on its industry-leading tech & AI stack, and clinically validated, already-deployed AI tests, such as RlapsRisk BC, to unlock morphological insights and future-proof the clinical diagnostic workflow.
![Figure 1: Fine-tuning improves robustness and performance jointly. Each foundation model is shown before (open circle) and after (filled circle) fine-tuning. The x-axis is the average PathoROB robustness index over three datasets, where higher values indicate greater robustness; the y-axis is the normalized rank sum over the HEST, THUNDER and Patho-Bench benchmarks, rescaled to [0, 1] so that 1 corresponds to the best achievable performance.](https://www.pathologynews.com/wp-content/uploads/2020/07/embedding-figure-800x600-1.png)
